联环药业：关于控股子公司获得《药品补充申请批准通知书》的公告

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of atropine sulfate injection [2] Group 1 - The approval is a significant regulatory milestone for the company, indicating progress in its product development and compliance with national standards [2] - Atropine sulfate injection is likely to enhance the company's product portfolio and potentially increase market competitiveness [2]